Your browser doesn't support javascript.
loading
Hunting for the elusive target antigen in gestational alloimmune liver disease (GALD).
Rieneck, Klaus; Rasmussen, Karen Koefoed; Schoof, Erwin M; Clausen, Frederik Banch; Holze, Henrietta; Bergholt, Thomas; Jørgensen, Marianne Hørby; Christensen, Vibeke Brix; Almaas, Runar; Jordal, Peter Lüttge; Locard-Paulet, Marie; Runager, Kasper; Nielsen, Leif Kofoed; Schlotmann, Balthasar Clemens; Weischenfeldt, Joachim Lütken; Jensen, Lars Juhl; Dziegiel, Morten Hanefeld.
Afiliação
  • Rieneck K; Laboratory of Blood Genetics, Department of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark.
  • Rasmussen KK; Laboratory of Blood Genetics, Department of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark.
  • Schoof EM; Department of Technology, Faculty of Health and Technology, University College Copenhagen, Copenhagen, Denmark.
  • Clausen FB; Department of Biotechnology and Biomedicine, Technical University of Denmark, Kgs. Lyngby, Denmark.
  • Holze H; Laboratory of Blood Genetics, Department of Clinical Immunology, Rigshospitalet, Copenhagen, Denmark.
  • Bergholt T; Novo Nordisk Foundation Center for Protein Research, Copenhagen, Denmark.
  • Jørgensen MH; Department of Obstetrics and Gynecology, Herlev Hospital, Herlev, Copenhagen, Denmark.
  • Christensen VB; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Almaas R; Department of Pediatric and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
  • Jordal PL; Department of Pediatric and Adolescent Medicine, Rigshospitalet, Copenhagen, Denmark.
  • Locard-Paulet M; Department of Pediatric Research, Oslo University Hospital, Oslo, Norway.
  • Runager K; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Nielsen LK; SBT Instruments A/S, Herlev, Denmark.
  • Schlotmann BC; Novo Nordisk Foundation Center for Protein Research, Copenhagen, Denmark.
  • Weischenfeldt JL; Teknologisk Institut, Aarhus C, Denmark.
  • Jensen LJ; Department of Technology, Faculty of Health and Technology, University College Copenhagen, Copenhagen, Denmark.
  • Dziegiel MH; Biotech Research & Innovation Centre, University of Copenhagen, Copenhagen, Denmark.
PLoS One ; 18(10): e0286432, 2023.
Article em En | MEDLINE | ID: mdl-37862305
ABSTRACT
The prevailing concept is that gestational alloimmune liver disease (GALD) is caused by maternal antibodies targeting a currently unknown antigen on the liver of the fetus. This leads to deposition of complement on the fetal hepatocytes and death of the fetal hepatocytes and extensive liver injury. In many cases, the newborn dies. In subsequent pregnancies early treatment of the woman with intravenous immunoglobulin can be instituted, and the prognosis for the fetus will be excellent. Without treatment the prognosis can be severe. Crucial improvements of diagnosis require identification of the target antigen. For this identification, this work was based on two hypotheses 1. The GALD antigen is exclusively expressed in the fetal liver during normal fetal life in all pregnancies; 2. The GALD antigen is an alloantigen expressed in the fetal liver with the woman being homozygous for the minor allele and the father being, most frequently, homozygous for the major allele. We used three different experimental approaches to identify the liver target antigen of maternal antibodies from women who had given birth to a baby with the clinical GALD diagnosis 1. Immunoprecipitation of antigens from either a human liver cell line or human fetal livers by immunoprecipitation with maternal antibodies followed by mass spectrometry analysis of captured antigens; 2. Construction of a cDNA expression library from human fetal liver mRNA and screening about 1.3 million recombinants in Escherichia coli using antibodies from mothers of babies diagnosed with GALD; 3. Exome/genome sequencing of DNA from 26 presumably unrelated women who had previously given birth to a child with GALD with husband controls and supplementary HLA typing. In conclusion, using the three experimental approaches we did not identify the GALD target antigen and the exome/genome sequencing results did not support the hypothesis that the GALD antigen is an alloantigen, but the results do not yield basis for excluding that the antigen is exclusively expressed during fetal life., which is the hypothesis we favor.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças do Sistema Digestório / Trombocitopenia Neonatal Aloimune / Doenças Fetais / Hemocromatose / Doenças do Recém-Nascido / Hepatopatias Limite: Child / Female / Humans / Newborn / Pregnancy Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Dinamarca

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças do Sistema Digestório / Trombocitopenia Neonatal Aloimune / Doenças Fetais / Hemocromatose / Doenças do Recém-Nascido / Hepatopatias Limite: Child / Female / Humans / Newborn / Pregnancy Idioma: En Revista: PLoS One Assunto da revista: CIENCIA / MEDICINA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Dinamarca